GlassScriptPhysician profile
Karen Kohatsu
NPI 1679517239
$18,083.95
in general payments reported to CMS, 2019-2025
39 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,524 · 2020: $933 · 2021: $8,152 · 2022: $3,917 · 2023: $1,258 · 2024: $1,181 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,545 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,544.80 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,908.87 | 2019-2021 | |
| Abbvie INC. | $5,577.24 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $1,365.79 | 2021-2025 | Bijuva |
| Evofem Biosciences, INC. | $496.10 | 2020-2025 | Solosec, Phexx, Phexxi |
| Sumitomo Pharma America, INC. | $482.73 | 2023-2025 | Myfembree, Gemtesa |
| Avion Pharmaceuticals | $378.40 | 2019-2022 | |
| Therapeuticsmd, INC. | $349.55 | 2019-2022 | |
| Myovant Sciences INC. | $275.11 | 2021-2022 | |
| Astellas Pharma US INC | $202.89 | 2024 | Veozah |
| Galderma Laboratories, L.P. | $201.14 | 2019-2021 | |
| Aspira Women'S Health INC | $174.84 | 2021-2024 | Ova1 |
| Exact Sciences Corporation | $166.25 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $124.77 | 2022 | |
| Organon LLC | $117.46 | 2021-2024 | |
| Hologic Sales and Service, LLC | $104.17 | 2020-2025 | Aptima |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $101.67 | 2019-2021 | |
| Coopersurgical, INC. | $101.66 | 2019-2023 | Paragard T 380a |
| Millicent US INC | $100.20 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Pfizer INC. | $95.93 | 2019-2023 | |
| Exeltis, USA INC. | $91.66 | 2020-2023 | Slynd |
| Lupin INC. | $86.39 | 2019-2020 | |
| Becton, Dickinson and Company | $85.97 | 2021-2024 | Bd Max System, Bd Max Instrument, Bd Onclarity |
| Merck Sharp & Dohme LLC | $76.28 | 2019-2021 | |
| Daiichi Sankyo INC. | $44.80 | 2022 | |
| Impel Pharmaceuticals INC. | $41.85 | 2023 | Trudhesa |
| Duchesnay USA Incorporated | $38.85 | 2019 | |
| Amag Pharmaceuticals, INC. | $35.91 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.68 | 2020 | |
| Mycovia Pharmaceuticals, INC. | $29.85 | 2022-2023 | Vivjoa |
| Minerva Surgical, INC | $27.75 | 2019 | |
| Revance Therapeutics, INC. | $24.40 | 2024 | Daxxify |
| Agile Therapeutics, INC. | $22.19 | 2021 | |
| Iroko Pharmaceuticals, LLC | $20.70 | 2019 | |
| Acella Pharmaceuticals, LLC | $18.12 | 2023 | NP Thyroid 60 |
| Myriad Women'S Health, INC. | $16.53 | 2023 | Myrisk |
| Olympus America INC. | $16.45 | 2022 | |
| Dysis Medical, INC. | $16.31 | 2022 | |
| Ascend Therapeutics US, LLC | $15.12 | 2022 | |
| Meditrina | $14.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Kohatsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.